

Press Release

Stockholm, Sweden, September 4, 2023

Mendus to participate in multiple investor and industry conferences in September

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:

H.C. Wainwright 25th Annual Global Investment Conference

New York, USA, September 11-13, 2023

Mendus CEO Erik Manting will participate and present a Company Update at the conference:

<https://hcwevents.com/annualconference/>

Pareto Securities' Annual Healthcare Conference

Stockholm, Sweden, September 14, 2023

Mendus CEO Erik Manting and CFO Lotta Ferm will participate and present a Company Update at the conference:

<https://paretosec.com/updates/events-and-conferences/>

CICON23 - International Cancer Immunotherapy Conference

Milan, Italy, September 20-23, 2023

Mendus to present preclinical and clinical data on the mode of action of its lead clinical program vidicencel

<http://www.cancerimmunotherapyconference.org/>

Nordic Conference and Opening Ceremony of NorthX Innovation Hub

Matfors, Sweden, September 27-28, 2023

Mendus Board member Hans Preusting will participate at the event:

<https://nxbio.confetti.events/>

ABOUT MENDUS AB (PUBL)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <http://www.mendus.com/>

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

INVESTOR RELATIONS

Corey Davis
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
E-mail: cdavis@lifesciadvisors.com

MEDIA RELATIONS

Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu